Diurnal Group plc announced that it has extended its distribution agreement with Er-Kim to include the distribution and marketing of Alkindi (hydrocortisone granules in capsules for opening) and Efmody (hydrocortisone modified-release hard capsules) in Greece, Cyprus and Malta. Under the terms of the agreement, Er-Kim will receive the exclusive rights to distribute and market Alkindi and Efmody in Greece, Cyprus and Malta. The company estimates the combined market opportunity for these three countries to be approximately €7 million in paediatric adrenal insufficiency (AI) and adult congenital adrenal hyperplasia (CAH).

This latest agreement deepens the company's existing relationship with Er-Kim, also hold the rights to distribute and market Alkindi and Efmody in Turkey, Romania and Bulgaria.